This study will assess the efficacy and safety of multiple doses of LCZ696 compared to
olmesartan in Asian patients with essential hypertension
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Inclusion Criteria:
- Patients with mild-to-moderate hypertension, untreated or currently taking
antihypertensive therapy.
- Treated patients (using antihypertensive treatments within 4 weeks prior to Visit
1) must have an msSBP≥150 mmHg and <180 mmHg at the randomization visit (Visit 201)
and msSBP≥140 mmHg <180 mmHg at the visit immediately preceding Visit 201 (Visit 102
or 103).
- Untreated patients (newly diagnosed with essential hypertension or having a history
of hypertension but have not been taking any antihypertensive drugs for at least 4
weeks prior to Visit 1) must have an msSBP≥150 mmHg and <180 mmHg at both Visit 1 and
Visit 201.
- Patients must have an absolute difference of ≤15 mmHg in msSBP between Visit 201 and
the immediately preceding visit.
Exclusion Criteria:
- Patients with severe hypertension (msDBP ≥110 mmHg and or msSBP ≥180 mmHg).
- History of angioedema, drug-related or otherwise, as reported by the patient.
- History or evidence of a secondary form of hypertension, including but not limited to
any of the following: renal parenchymal hypertension, renovascular hypertension
(unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary
hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease,
and drug-induced hypertension.
- Patients who previously entered a LCZ696 study and had been randomized or enrolled
into the active drug treatment epoch.
Other protocol-defined inclusion/exclusion criteria may apply.
Novartis Investigative Site, Beijing 100034, China
Novartis Investigative Site, Beijing 100029, China
Novartis Investigative Site, Beijing 100020, China
Novartis Investigative Site, Fuzhou 350001, China
Novartis Investigative Site, Shanghai 200032, China
Novartis Investigative Site, Shanghai 200025, China
Novartis Investigative Site, Shanghai 200031, China
Novartis Investigative Site, Tianjin 300142, China
Novartis Investigative Site, Hong Kong, Hong Kong
Novartis Investigative Site, Seoul 738-736, Korea, Republic of
Novartis Investigative Site, Seoul 152-703, Korea, Republic of
Novartis Investigative Site, Seoul 137-701, Korea, Republic of
Novartis Investigative Site, Quezon City 1100, Philippines
Novartis Investigative Site, Quezon City 1102, Philippines
Novartis Investigative Site, Singapore 169609, Singapore
Novartis Investigative Site, Kaohsiung 807, Taiwan
Novartis Investigative Site, Kaohsiung 82445, Taiwan
Novartis Investigative Site, New Taipei City 23561, Taiwan
Novartis Investigative Site, Taichung 40447, Taiwan
Novartis Investigative Site, Taipei County, Taiwan
Novartis Investigative Site, Taipei 10002, Taiwan
Novartis Investigative Site, Taipei 110, Taiwan
Novartis Investigative Site, Yun-Lin 640, Taiwan
Novartis Investigative Site, Bangkok 10700, Thailand
Novartis Investigative Site, Chiang Mai 50200, Thailand
Novartis Investigative Site, Khon Kaen 40002, Thailand
Novartis Investigative Site, Rajathevee 10400, Thailand
Novartis Investigative Site, Beijing, Beijing 100044, China
Novartis Investigative Site, Chongqing, Chongqing 400042, China
Novartis Investigative Site, Chongqing, Chongqing, China
Novartis Investigative Site, Fuzhou, Fujian, China
Novartis Investigative Site, Guangzhou, Guangdong 510030, China
Novartis Investigative Site, Guangzhou, Guangdong 510080, China
Novartis Investigative Site, Nanning, Guangxi 530021, China
Novartis Investigative Site, Shijiazhuang, Hebei 050000, China
Novartis Investigative Site, Harbin, Heilongjiang 150001, China
Novartis Investigative Site, Wuhan, Hubei 430030, China
Novartis Investigative Site, Changsha, Hunan 410003, China
Novartis Investigative Site, Nanjing, Jiangsu 210009, China
Novartis Investigative Site, Suzhou, Jiangsu 215006, China
Novartis Investigative Site, Nanchang, Jiangxi 330006, China
Novartis Investigative Site, Seoul, Korea 110 744, Korea, Republic of
Novartis Investigative Site, Koyang, Kyunggi 410-719, Korea, Republic of
Novartis Investigative Site, Shenyang, Liaoning 110016, China
Novartis Investigative Site, Shanghai, Shanghai 200072, China
Novartis Investigative Site, Shanghai, Shanghai 200120, China
Novartis Investigative Site, Xi'an, Shanxi 710004, China
Novartis Investigative Site, Xi'an, Shanxi 710061, China
Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan
Novartis Investigative Site, Tianjin, Tianjin 300121, China
Novartis Investigative Site, Hangzhou, Zhejiang 310013, China